Business Wire

Synack Commits to Supporting the Advancement of Women in Cybersecurity by Launching a Courageous Women in Security Initiative

Share

New York Times reporter Jessica Bennett observed that the 2020 female Democratic candidates have largely avoided the phrase “glass ceiling”, prompting linguist Robin Lakoff to speculate that the phrase just “seems tired”. On the debate floor, action-oriented and empowering words like “persist” are replacing phrases like “glass ceiling” and the “stuck-ness” implicitly suggested by them. It’s not just in politics that women are intentionally working toward changing society’s perception of them in the workplace; it’s happening in cybersecurity too.

Today, women make up only 20% of the cybersecurity industry’s workforce. This largely untapped demographic could be the saving grace for an industry desperate for skilled labor and on pace to hit 3.5 million unfilled jobs by 2021 according to Cybersecurity Ventures. This is why today Synack launches their “Courageous Women CISO Initiative” which aims to encourage more women to enter the cybersecurity field; offer support by creating a strong network for women; and provide a platform for women to share their voice in the boardroom, across the aisles in policy, and from the podium at leading industry conferences. Synack will build upon efforts that aim to close the talent gap in other ways (like encouraging young women to enter into STEM fields) by empowering women to get to the forefront of cybersecurity innovation and lead the charge in making our organizations more secure. The company is also encouraging more women to apply to their elite Synack Red Team, the world’s best and most trusted crowd of ethical hackers.

“When the concept of harnessing a crowd of ethical hackers was novel, Synack found that women CISOs were 2x more likely to adopt crowdsourced security, which showed that female security leaders are willing to be bold and courageous when facing decisions that can make their organizations more secure. Cybersecurity is a field that needs more diversity in thought and action, and women are an underrepresented group. We need more female leaders in the field who have successfully navigated the industry to be examples and mentors to newcomers,” said Aisling MacRunnels, Synack CMO and Courageous Women CISO Initiative Chair.

Synack’s initiative aims to connect and empower security’s female change-makers through a series of networking events and opportunities to speak from the podium at industry-renowned conferences. Synack has partnered with Microsoft/M12, CyberWire and now Booz Allen Hamilton to host popular women’s networking events at Black Hat USA, RSA Conference, and Billington Cybersecurity Summit; later this week, the company will host their 3rd annual Women’s Brunch at Black Hat USA. Through these efforts, Synack aims to …

  • Close the talent gap in cybersecurity by increasing the number of women entering the industry by 50% by 2022.
  • Increase the number of women speaking at industry conferences, so that the percentage of female speakers is on par with the percentage of male speakers by 2022.

After the women’s lunch at the RSA Conference 2019, partners M12 and CyberWire said, “We had a great time with the Synack team today - if only every lunch could be filled with so many impressive women! A big thank you to our amazing hosts: Lisa Nelson, Microsoft Ventures and Aisling MacRunnels, Synack,” (M12), and “It is our pleasure to support and empower women in the field of cybersecurity!” (Cyberwire).

Synack’s Courageous Women CISO initiative was developed to bring female security leaders and executives together to support each other in having a bigger impact in their companies and industry. Through this initiative, Synack’s goal is to create an environment that fosters authentic conversations and provides a support network for women in cybersecurity. Let’s change the status quo in cybersecurity together - RSVP for upcoming events for women and learn more about Synack’s Courageous Women CISO Initiative here: https://go.synack.com/courageous-women-ciso.html.

About Synack

Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com.

Contact information

Ellie McCardwell, Synack Communications
press@synack.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing